Aldosterone and aldosterone synthase inhibitors in cardiorenal disease

Subodh Verma, Avinash Pandey, Arjun K. Pandey, Javed Butler, John S. Lee, Hwee Teoh, C. David Mazer, Mikhail N. Kosiborod, Francesco Cosentino, Stefan D. Anker, Kim A. Connelly, Deepak L. Bhatt

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations

Abstract

Modulation of the renin-angiotensin-aldosterone system is a foundation of therapy for cardiovascular and kidney diseases. Excess aldosterone plays an important role in cardiovascular disease, contributing to inflammation, fibrosis, and dysfunction in the heart, kidneys, and vasculature through both genomic and mineralocorticoid receptor (MR)-mediated as well as nongenomic mechanisms. MR antagonists have been a key therapy for attenuating the pathologic effects of aldosterone but are associated with some side effects and may not always adequately attenuate the nongenomic effects of aldosterone. Aldosterone is primarily synthesized by the CYP11B2 aldosterone synthase enzyme, which is very similar in structure to other enzymes involved in steroid biosynthesis including CYP11B1, a key enzyme involved in glucocorticoid production. Lack of specificity for CYP11B2, off-target effects on the hypothalamic-pituitary-adrenal axis, and counterproductive increased levels of bioactive steroid intermediates such as 11-deoxycorticosterone have posed challenges in the development of early aldosterone synthase inhibitors such as osilodrostat. In early-phase clinical trials, newer aldosterone synthase inhibitors demonstrated promise in lowering blood pressure in patients with treatment-resistant and uncontrolled hypertension. It is therefore plausible that these agents offer protection in other disease states including heart failure or chronic kidney disease. Further clinical evaluation will be needed to clarify the role of aldosterone synthase inhibitors, a promising class of agents that represent a potentially major therapeutic advance.

Original languageEnglish
Pages (from-to)H670-H688
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume326
Issue number3
DOIs
StatePublished - Mar 2024
Externally publishedYes

Keywords

  • aldosterone
  • aldosterone synthase inhibitor
  • hypertension
  • mineralocorticoid receptor
  • renin-angiotensin-aldosterone system

Fingerprint

Dive into the research topics of 'Aldosterone and aldosterone synthase inhibitors in cardiorenal disease'. Together they form a unique fingerprint.

Cite this